Searchable abstracts of presentations at key conferences in endocrinology

ea0022p221 | Clinical case reports and clinical practice | ECE2010

Two therapeutic approaches for thyrotropin-secreting pituitary adenomas

Sambo Marcel , Garcia Rogelio , Fernandez Elisa , Andia Victor , Lezcano Diego , Alvarez Pilar , Rodriguez Paloma

Case 1: Thirty-eight year woman consulted to gynecologist for oligomenorrhea in the last 4 years; PRL 51 μg/l and TSH 8.4 mU/l were discovered, initiating treatment with levotiroxine (f-T4). She got pregnant, persisting elevated levels of TSH and increasing f-T4, with normal campimetry. With the diagnostic of hyperthyroidism due to inadequate TSH secretion, treatment with PTU was initiated. After normal delivery, MRI showed a 22 mm. hypophisary macroadenoma and a transesp...

ea0022p328 | Diabetes | ECE2010

Follow up of type 1 diabetic patients treated with insulin continuous s.c. infusion

Andia Victor M , Fernandez Elisa , Jara Antonino , Garcia Rogelio , Sambo Marcel , Lezcano Diego A

Insulin continuous s.c. infusion (ICSI) is an alternative therapy in selected diabetic patients when a good metabolic control is not achieved with multiple insulin doses (MID). We report the follow-up of patients with ICSI at least during 1 year in our centre.Patients and methods: Twenty-five patients (16 females, 9 males), with median age 38.4±12.5 years and diabetes evolution mean time 16.8±7.8 years, were changed from MID to ICSI due to defi...

ea0056p138 | Endocrine tumours and neoplasia | ECE2018

Evaluation of neurofibromatosis type 1 and gastroenteropancreatic neuroendocrine tumors.

Percovich Juan Carlos , Atencia Jose , Garcia Rogelio , Sambo Marcel , Blanco Montserrat , Rotger Amanda , Lopez Dolores , Olmedilla Yoko , Picallo Maria , Velez Marian , Agreda Javier , Brox Noemi , Monereo Susana

Introduction: Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with an incidence of 1 in 2600 to 3000 individuals. Patients with this disorder are characterized by multiple neurofibromas, caf-au-lait macules, axillary freckling, optic gliomas, iris hamartomas, and skeletal abnormalities. Overall risk of developing neoplasms is approximately 2 to 4-fold higher in patients with NF1, with a risk of malignancy estimated between 5 and 15%. Endocrinopathies are some...

ea0063p1106 | Pituitary and Neuroendocrinology 3 | ECE2019

Analysis of gender-related differences in clinically non-functioning pituitary adenomas

Aguirre Moreno Nerea , Sampedro-Nunez Miguel , Levi Ana Ramos , Centeno Rogelio Garcia , Carrera Concepcion Blanco , Escola Cristina Alvarez , Novoa Paz de Miguel , Gutierrez Maria Calatayud , Librizzi Soledad , Azpiroz Monica Marazuela

Introduction: Clinically non-functioning pituitary adenomas (NFPA) are heterogeneous group. Some previous research has found that this type of pituitary adenomas may be smaller and have better prognostic in men. The aim of this study is to analyze if there are gender-related differences in NFPA.Material and methods: Retrospective study of patients with NFPA followed up in regional hospitals (Community of Madrid, Spain). All NFPA had molecular analysis. T...

ea0049ep1030 | Pituitary - Clinical | ECE2017

Hormone and tumor responses to primary or pre-operative therapy with somatostatin analogs in acromegaly and the relation with T2-weighted MRI signal

Picallo Maria , Centeno Rogelio Garcia , Guerra Aurelio Lopez , Olmedilla Yoko Lucia , Arnoriaga Maria , Requena Maria , Agreda Javier , Andia Victor , Sambo Marcel , Monereo Susana , Velez Maria Angeles , Weber Bettina , Atencia Jose

Objective: Study of the efficacy of SSA in the biochemical and tumour control and the relation between the T2-weighted MRI signal intensity and the response to SSA.Material and methods: 16 patients with GH-secreting pituitary adenomas (7♂/9♀) that received primary or pre-operative treatment with SSA. We classified them according to baseline T2-weighted MRI sequences as Hypo-intense (Ha) and No-Hypo-intense adenomas (no-Ha). Results expressed ...

ea0035p237 | Clinical case reports Pituitary/Adrenal | ECE2014

Hyperprolactinemia secondary to primary hypothyroidism with hyperplasia pituitary

Centeno Rogelio Garcia , Melero Victor Andia , Fernandez Elisa Fernandez , Salas Marcel Sambo , Gonzalez-Antiguedad Cynthia , de la Camara Marta Motilla , Solis Diego Lezcano , Gonzalez Javier , Rivadeneira Lenin , Requena Maria , Ramirez Maria Laura , Olmedilla Yoko , Arnoriaga Maria

Introduction: Although the most common causes of hyperprolactinemia are prolactinoma and iatrogenic, another possible cause is severe primary hypothyroidism, in which the increase of prolactin is a cause of pituitary stimulation by TRH, and can be presented with pituitary hyperplasia.Case report: A 31-year-old woman who comes to endocrinology clinic for hyperprolactinemia, which was detected by symptoms of amenorrhea–galactorrhea. After normal pregn...

ea0035p445 | Diabetes complications | ECE2014

Autoimmune pancreatitis after intravenous insulin desensitization in a diabetic patient allergic to insulin without pancreatic reserve

Salas Marcel Sambo , Melero Victor Andia , Ishishi Yoko Olmedilla , Centeno Rogelio Garcia , Ramirez Maria Laura , Motilla Marta , Antiguedad Cynthia Gonzalez , Requena Maria , Lopez Javier Gonzalez , Rivadeneira Lenin , Arnoriaga Maria

Introduction: Allergy is an uncommon side-effect of insulin treatment in which desensitization represents an alternative when initial approaches are not effective. Autoimmune pancreatitis (AIP) is an even more rare disease that generally has a successful response to corticosteroids. The case of a 50-year-old diabetic man who developed both processes sequentially is presented.Case report: The patient was admitted for acute diabetes mellitus (DM) decompens...

ea0090ep730 | Pituitary and Neuroendocrinology | ECE2023

Precision medicine in acromegaly: results of the ACROFAST study

Puig-Domingo Manel , Marques-Pamies Montserrat , Gil Joan , Valassi Elena , Gimenez-Palop Olga , Hernandez Marta , Taibo Rocio Villar , Biagetti Betina , Villarroya Gemma Xifra , Simo-Servat Andreu , Zavala Roxana , Simon Inmaculada , Araujo-Castro Marta , Centeno Rogelio Garcia , Calatayud Maria , Miguel Federico Vazquez San , Vilarrasa N , Vert Isabel Salinas , Mora Mireia , Hanzu Felicia Alexandra , Novoa Maria Paz De Miguel , Pavon Isabel , Blanco Concepcion , Alvarez-Escola Cristina , Sampedro-Nunez Miguel Antonio , Jorda Mireia , Bernabeu Ignacio , Webb Susan , Marazuela Monica

Medical treatment of acromegaly is currently performed through a trial-error manner using somatostatin receptor ligands (SRLs) as first-line drugs. Average SRLs response is seen in 50% of cases; subsequent drugs are indicated following clinical judgement. Some biomarkers either before or after surgical failure have been reported to predict SRLs response, including intensity in T2 weighted MRI, short acute octreotide test (sAOT), and different molecules such as SST2 and E-cadhe...